克罗恩病的中医证候临床研究

注册号:

Registration number:

ITMCTR2024000743

最近更新日期:

Date of Last Refreshed on:

2024-11-27

注册时间:

Date of Registration:

2024-11-27

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

克罗恩病的中医证候临床研究

Public title:

Clinical Research on Traditional Chinese Medicine Syndromes of Crohn's Disease

注册题目简写:

English Acronym:

研究课题的正式科学名称:

克罗恩病的中医证候临床研究

Scientific title:

Clinical Research on Traditional Chinese Medicine Syndromes of Crohn's Disease

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

姚钧仁

研究负责人:

林江

Applicant:

Yao Junren

Study leader:

Lin Jiang

申请注册联系人电话:

Applicant telephone:

13585966913

研究负责人电话:

Study leader's telephone:

18917763419

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

jryao_kevin@163.com

研究负责人电子邮件:

Study leader's E-mail:

linjiang@longhua.net

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

上海市徐汇区宛平南路725号

研究负责人通讯地址:

上海市徐汇区宛平南路725号

Applicant address:

No.725 South Wanping Road Xuhui District Shanghai

Study leader's address:

No.725 South Wanping Road Xuhui District Shanghai

申请注册联系人邮政编码:

Applicant postcode:

200032

研究负责人邮政编码:

Study leader's postcode:

200032

申请人所在单位:

上海中医药大学附属龙华医院

Applicant's institution:

Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2023LCSY090

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

上海中医药大学附属龙华医院伦理审查委员会

Name of the ethic committee:

Institutional Review Board Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2023/11/30 0:00:00

伦理委员会联系人:

陈晓云

Contact Name of the ethic committee:

Chen Xiaoyun

伦理委员会联系地址:

上海市徐汇区宛平南路725号

Contact Address of the ethic committee:

No.725 South Wanping Road Xuhui District Shanghai

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 021-64385700-11318

伦理委员会联系人邮箱:

Contact email of the ethic committee:

lhtcmirb@sina.cn

研究实施负责(组长)单位:

上海中医药大学附属龙华医院

Primary sponsor:

Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

上海市徐汇区宛平南路725号

Primary sponsor's address:

No.725 South Wanping Road Xuhui District Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海市

市(区县):

上海市

Country:

China

Province:

Shanghai

City:

单位(医院):

上海中医药大学附属龙华医院

具体地址:

上海市徐汇区宛平南路725号

Institution
hospital:

Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine

Address:

No.725 South Wanping Road Xuhui District Shanghai

经费或物资来源:

上海市进一步加快中医药传承创新发展三年行动计划(2021年-2023年)

Source(s) of funding:

Further Accelerate the Three-Year Action Plan for the Inheritance Innovation and Development of Traditional Chinese Medicine in Shanghai(2021-2023)

研究疾病:

克罗恩病

研究疾病代码:

Target disease:

Crohn's Disease

Target disease code:

研究类型:

Study type:

观察性研究

Observational study

研究设计:

Study design:

横断面

Cross-sectional

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

通过研究克罗恩病的中医证候分布规律,来认识克罗恩病的中医病机,为今后开展克罗恩病的中医辨证施治奠定基础。

Objectives of Study:

By studying the distribution patterns of Traditional Chinese Medicine (TCM) syndromes in Crohn's disease, this research aims to elucidate the TCM pathogenesis of the condition, thereby laying a foundational basis for the future implementation of TCM syndrome differentiation and treatment in Crohn's disease.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1)符合克罗恩病诊断标准的患者;2)入组前2周内完善血常规、ESR、CRP、凝血功能、FC、结肠镜/胶囊内镜/小肠镜等理化检查;3)年龄在14岁以上,性别不限;4)自愿接受本临床研究,签署知情同意书。

Inclusion criteria

1) Patients who meet the diagnostic criteria for Crohn's disease; 2) Completion of comprehensive laboratory tests including complete blood count erythrocyte sedimentation rate (ESR) C-reactive protein (CRP) coagulation function fecal calprotectin (FC) and colonoscopy/capsule endoscopy/enteroscopy within two weeks prior to enrollment; 3) Individuals aged 14 years and older regardless of gender; 4) Voluntary participation in this clinical study with signed informed consent.

排除标准:

1)不能除外溃疡性结肠炎、肠结核、肠白塞病、感染性肠炎、缺血性结肠炎、放射性肠炎、药物性肠病、嗜酸粒细胞性肠炎、以肠道病变为突出表现的多种风湿性疾病(如系统性红斑狼疮、原发性血管炎等)、肠道恶性淋巴瘤等。2)合并严重的循环系统、呼吸系统、血液系统、内分泌系统或恶性肿瘤等疾病者。3)伴有严重神经功能缺损或精神疾病者。4)经研究者判断,调查不配合或其他增加入组复杂性情况的患者。

Exclusion criteria:

1)Patients with ulcerative colitis intestinal tuberculosis Behçet's disease infectious enteritis ischemic colitis radiation enteritis drug-induced enteropathy eosinophilic enteritis and various rheumatic diseases with gastrointestinal manifestations (such as systemic lupus erythematosus primary vasculitis etc.) as well as gastrointestinal malignant lymphoma cannot be excluded.2)Patients with severe diseases of the circulatory system respiratory system hematologic system endocrine system or malignancies. 3) Patients with significant neurological deficits or psychiatric disorders. 4)Patients deemed by the investigator to be uncooperative or those with other factors that complicate the enrollment process.

研究实施时间:

Study execute time:

From 2024-12-01

To      2026-02-28

征募观察对象时间:

Recruiting time:

From 2024-12-01

To      2025-11-30

干预措施:

Interventions:

组别:

受试组

样本量:

430

Group:

Experimental group

Sample size:

干预措施:

填写《克罗恩病中医证候量表》

干预措施代码:

Intervention:

Filling out the "Traditional Chinese Medicine Symptom Scale for Crohn's Disease"

Intervention code:

样本总量 Total sample size : 430

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

上海市

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海中医药大学附属龙华医院

单位级别:

三级甲等

Institution/hospital:

Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

肠道黏膜活检

指标类型:

次要指标

Outcome:

Intestinal Mucosal Biopsy

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血沉

指标类型:

次要指标

Outcome:

erythrocyte sedimentation rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

粪便钙卫蛋白

指标类型:

次要指标

Outcome:

fecal calprotectin

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血常规

指标类型:

次要指标

Outcome:

blood routine

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

舌象

指标类型:

主要指标

Outcome:

Tongue Manifestation

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胶囊内镜

指标类型:

次要指标

Outcome:

Capsule Endoscopy

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

脉象

指标类型:

主要指标

Outcome:

Pulse diagnosis

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

小肠镜

指标类型:

次要指标

Outcome:

Small bowel endoscopy

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

结肠镜

指标类型:

次要指标

Outcome:

Colonoscope

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

C-反应蛋白

指标类型:

次要指标

Outcome:

c-reactive protein

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

凝血功能

指标类型:

次要指标

Outcome:

Coagulation Function

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

肠道组织

组织:

Sample Name:

Intestinal tissue

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

粪便

组织:

Sample Name:

Feces

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 14
Min age years
最大 80
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

依托学校及医院科研平台进行共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Sharing scientific research based on platform of schools and hospitals

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据通过手写记录及电子保存、整理、归纳,并按时填写患者病历报告表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

data by hand written records and electronic storage sorting induction and on time to fill in patients with case report

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统